UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.94-0.67 (-5.31%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5597.62M
Enterprise value 3430.93M
Trailing P/E 41.17
Forward P/E 1-14.92
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)4.64
Price/book (mrq)2.59
Enterprise value/revenue 33.34
Enterprise value/EBITDA 735.76

Trading information

Stock price history

Beta (5Y monthly) 1.10
52-week change 3-31.22%
S&P500 52-week change 336.19%
52-week high 329.65
52-week low 311.80
50-day moving average 313.82
200-day moving average 317.78

Share statistics

Avg vol (3-month) 3862.08k
Avg vol (10-day) 3417.04k
Shares outstanding 550.05M
Implied shares outstanding 6N/A
Float 42.27M
% held by insiders 110.50%
% held by institutions 168.45%
Shares short (29 Jun 2021) 43.17M
Short ratio (29 Jun 2021) 45.09
Short % of float (29 Jun 2021) 46.47%
Short % of shares outstanding (29 Jun 2021) 46.34%
Shares short (prior month 27 May 2021) 43.15M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:2
Last split date 315 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021

Profitability

Profit margin 10.88%
Operating margin (ttm)9.17%

Management effectiveness

Return on assets (ttm)3.31%
Return on equity (ttm)7.18%

Income statement

Revenue (ttm)128.92M
Revenue per share (ttm)2.67
Quarterly revenue growth (yoy)-76.10%
Gross profit (ttm)27.23M
EBITDA 12.05M
Net income avi to common (ttm)14.03M
Diluted EPS (ttm)0.29
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)171.58M
Total cash per share (mrq)3.43
Total debt (mrq)4.89M
Total debt/equity (mrq)2.12
Current ratio (mrq)11.40
Book value per share (mrq)4.61

Cash flow statement

Operating cash flow (ttm)9.1M
Levered free cash flow (ttm)3.32M